Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study
Pirtobrutinib,一种高选择性、非共价(可逆)BTKi,用于治疗复发/难治性边缘区淋巴瘤:BRUIN 1/2期研究
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025017489
Patel, Krish; Vose, Julie M; Nasta, Sunita D; Brown, Jennifer R; Maddocks, Kami J; Woyach, Jennifer A; Shah, Nirav N; Fakhri, Bita; Tessoulin, Benoit; Ma, Shuo; Jagadeesh, Deepa; Lech-Maranda, Ewa; Coombs, Catherine C; Patel, Manish R; Rhodes, Joanna M; Ujjani, Chaitra; Hoffmann, Marc S; Cheah, Chan Y; Munir, Talha; Lewis, David; Scarfò, Lydia; Eyre, Toby A; Alencar, Alvaro; Cohen, Jonathon B; Zelenetz, Andrew D; Tsai, Donald E; Li, Mei; Bian, Yuanyuan; Abada, Paolo; Balbas, Minna; Zinzani, Pier Luigi